Navigation Links
Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
Date:5/6/2009

STOCKHOLM, May 6 /PRNewswire/ -- Axelar AB today announced successful completion of the single-day oral dosing part of its ongoing phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717,an insulin-like growth factor-1 (IGF-1) receptor inhibitor which has no effects on the closely related insulin receptor. The study is conducted in Sweden on patients having terminal cancer disease. The results showed that a single-day dosing of AXL1717 could be successfully escalated with excellent tolerability. No dose-limiting toxicity was reported. The next part of the trial has now been approved, including a seven-day dosing BID regimen instead of single-day BID treatments. The first patients have already been treated with AXL1717 for seven days.

The ongoing phase I/II clinical trial is primarily designed to assess the safety, tolerability, and pharmacokinetics of the drug. As a secondary objective, anti-cancer effects are documented whenever possible.

"We are very pleased that high doses of AXL1717 could be administered to patients without significant side effects during the single-day treatments.", says Johan Harmenberg, CEO of Axelar AB. "Targeting cancer cells with AXL1717 instead of conventional cytotoxic chemotherapy may be a new and well-tolerated treatment alternative for cancer patients in the future."

The IGF-1 receptor is a promising target for the treatment of cancer, since the receptor is crucial for the survival and growth of malignant cells. In contrast, the IGF-1 receptor is not absolutely necessary for growth of normal cells.

AXL1717 is a small-molecule IGF-1 receptor inhibitor with no effect on the important and almost identical insulin receptor. Pre-clinical data show an extraordinary anti-tumor efficacy in animal models, including apparent complete tumor regression, for a wide range of human cancers such as breast cancer, prostate cancer, malig
'/>"/>

SOURCE Karolinska Development AB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
2. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
3. VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities
4. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
5. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
6. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
7. DiFUSION Technologies Completes Successful Testing of Antimicrobial Spinal Implant
8. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
9. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
10. Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation
11. Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Fayetteville, Arkansas (PRWEB) December 18, 2014 ... plans to locate its pilot production facility and ... further develop and produce innovative new materials that ... was chosen not only because of its historic, ... regional leaders’ efforts to attract leading edge, technology-based ...
(Date:12/19/2014)... Boston, MA (PRWEB) December 18, 2014 ... software, announced the appointment of Siri Bryant as the ... the new Director of Core Implementations. These two new ... provide outstanding customer service by ensuring that iLab continues ... , “In the last four years, iLab has been ...
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group finds ... biomaterial market will grow moderately through 2023 as the ... growing awareness of dental biomaterials all spur procedure volumes. ... as China and ... dental procedures within reach for a larger proportion of ...
(Date:12/17/2014)... The Activated Carbon Manufacturing ... why IBISWorld updated its original industry research report. ... an intensified focus on environmental policy. Over the five ... for power plants and a range of other industrial ... Analyst Sarah Kahn, “a range of downstream industrial sectors ...
Breaking Biology Technology:Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3
... Corporation,(Nasdaq: NEOG ) announced today that it ... Winnipeg, Canada. Rivard Instruments and Neogen,s,subsidiary, Ideal Instruments, ... The acquisition settles lengthy litigation between the ... patent battles were centered,on lawsuits filed by Ideal ...
... (marketed as Gleevec in the US and Glivec in ... including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors ... distinct types of cancer because they are caused by ... specificity for a single protein means that imatinib can ...
... 3 Thermo Fisher,Scientific Inc. (NYSE: TMO ), ... China Doping Control Center (CDCC) has selected the,company as ... for,the testing of athletes at the 29th Olympic Games ... government and the International Olympic,Committee (IOC) to conduct all ...
Cached Biology Technology:Neogen Acquires Assets of Rivard Instruments 2Thermo Fisher Scientific Selected by China Doping Control Center to Supply Testing Instrumentation for the 2008 Olympic Games in Beijing 2Thermo Fisher Scientific Selected by China Doping Control Center to Supply Testing Instrumentation for the 2008 Olympic Games in Beijing 3Thermo Fisher Scientific Selected by China Doping Control Center to Supply Testing Instrumentation for the 2008 Olympic Games in Beijing 4
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in ... sensors in biomedical applications. Chemical sensors help in ... diagnosis during surgical procedures. The Global Chemical Sensor ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... A Florida State University faculty member who uses ... cancer-killing drugs is attracting worldwide attention from other ... of chemical and biomedical engineering at the Florida ... using high-powered computers to determine how substances known ...
... at North Carolina State University have found that quantum ... an abrasion, providing insight into potential workplace concerns for ... quantum dots or doing research on potential biomedical applications ... that quantum dots of different sizes, shapes and surface ...
... July 2, 2008 Volunteers representing the Juvenile Diabetes ... and the National Indian Health Board (NIHB) will present ... for his leadership on extending the Special Diabetes Program ... at 11:30 a.m. in the Buchli Room at the ...
Cached Biology News:FSU researcher using computers to hone cancer-fighting strategies 2Study shows quantum dots can penetrate skin through minor abrasions 2Sen. Byron Dorgan to be honored 2
... 500 Series is a sophisticated ... most advanced technologies available. The ... testing, powerful software and a ... researchers optimize their overall workflow ...
... of a protein into cells permits studies ... pathways, apoptotic pathways, and transcription factor-mediated gene ... the effects of a specific protein in ... protein directly into the cell. ProteoJuice Protein ...
Reacti-Bind DNA Coating Solution...
Immunogen GST fusion protein corresponding to full-length rat JNK3/ SAPK1b. Quality Assurance Routinely evaluated by immunoblot. Stability 2 years at -20°C from date of shipment GenBank A...
Biology Products: